A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05336409 |
Recruitment Status :
Recruiting
First Posted : April 20, 2022
Last Update Posted : April 23, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
R/R CD19-Positive B-Cell Malignancies Indolent Non-Hodgkin Lymphoma Aggressive Non-Hodgkin Lymphoma | Biological: CNTY-101 Biological: IL-2 Drug: Lymphodepleting Chemotherapy | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 75 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies |
Actual Study Start Date : | January 24, 2023 |
Estimated Primary Completion Date : | August 2025 |
Estimated Study Completion Date : | August 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose Escalation: Schedule A
Lymphodepleting chemotherapy (LDC) will be followed by single dose administration of CNTY-101, alone or with supplemental human recombinant interleukin 2 (IL-2).
|
Biological: CNTY-101
CNTY-101 cells for intravenous (IV) infusion Biological: IL-2 IL-2 subcutaneous (SQ) injection Drug: Lymphodepleting Chemotherapy LDC as prespecified in the protocol. |
Experimental: Dose Escalation: Schedule B
LDC will be followed by administration of CNTY-101, 3 times over 3 weeks, alone or with supplemental IL-2.
|
Biological: CNTY-101
CNTY-101 cells for intravenous (IV) infusion Biological: IL-2 IL-2 subcutaneous (SQ) injection Drug: Lymphodepleting Chemotherapy LDC as prespecified in the protocol. |
- Maximum Tolerated Dose (MTD) as Determined by the Percentage of Participants With Dose Limiting Toxicities (DLTs) and DLTs Based on Severity [ Time Frame: Up to 28 days ]
- Recommended Phase 2 Regimen (RP2R) as Recommended by the Safety Review Committee (SRC) [ Time Frame: Up to 28 days ]
- Complete Response Rate (CRR) Based on Percentage of Participants Achieving Complete Response (CR) [ Time Frame: Up to 2 years ]CRR will be determined using Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.
- Objective Response Rate (ORR) Based on Percentage of Participants Achieving CR or Partial Response (PR) [ Time Frame: Up to 2 years ]ORR will be determined using Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.
- Duration of Response (DOR) [ Time Frame: Up to 2 years ]DOR is defined as time from first response (CR or PR) to the first documentation of progressive disease (PD) or death.
- Time to Treatment Response (TTR) [ Time Frame: Day 1 up to 2 years ]TTR is defined as time from first CNTY-101 infusion to the first documentation of response (CR or PR).
- Progression-Free Survival (PFS) [ Time Frame: Day 1 up to 2 years ]PFS is defined as time from first CNTY-101 infusion to the first documentation of PD, or death from any cause, whichever occurs first
- Overall Survival (OS) [ Time Frame: Day 1 up to 2 years ]OS is defined as time from CNTY-101 infusion to death.
- Cmax: Maximum Observed Plasma Concentration for CNTY-101 [ Time Frame: Day 1 up to 2 years ]
- Tmax: Time to Reach the Maximum Plasma Concentration for CNTY-101 [ Time Frame: Day 1 up to 2 years ]
- t1/2: Terminal Disposition Phase Half-life for CNTY-101 [ Time Frame: Day 1 up to 2 years ]
- AUC: Area under the Concentration-time Curve for CNTY-101 [ Time Frame: Day 1 up to 2 years ]
- Percentage of Participants With at Least one Treatment Emergent Adverse Event (TEAE) [ Time Frame: Day 1 up to 2 years ]
- Percentage of Participants With Clinically Significant Laboratory Abnormalities [ Time Frame: Day 1 up to 2 years ]
- Time to Treatment Initiation [ Time Frame: Enrollment to first CNTY-101 infusion (up to approximately 2 weeks) ]Time to treatment initiation is defined as the time from enrollment in the study to first CNTY-101 infusion.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
-
Must have met the following criteria for prior treatment:
- Participants with aggressive NHL must have received at least 2 lines of systemic therapy (if not intended for transplant, have already undergone or be unwilling or unable to undergo chimeric antigen receptor [CAR] T-cell therapy to be eligible), or at least 3 lines of systemic therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline or alkylator.
- Participants with follicular lymphoma (FL) must have received at least 2 lines of systemic therapy and have high-risk disease. Previous therapy must have included a CD20-targeted agent and an alkylator.
- Participants with marginal zone lymphoma (MZL) must have received at least 2 prior systemic therapies.
- Measurable disease on screening evaluations.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function.
- Life expectancy of ≥12 weeks.
Exclusion Criteria:
- Any condition that confounds the ability to interpret data from the study.
- Central nervous system (CNS)-only involvement by malignancy. (Note: participants with secondary CNS involvement are allowed.)
- Prior allogeneic stem cell transplant.
- Presence of clinically significant CNS pathology.
- Other comorbid conditions defined in the protocol.
- Use of prohibited medications within the washout period defined in the protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05336409
Contact: Nikolaus Trede | 888-506-7670 | ClinicalTeamCNTY@centurytx.com |
United States, Arizona | |
Banner MD Anderson Cancer Center | Recruiting |
Gilbert, Arizona, United States, 85234 | |
Contact: Dr. Matthew Ulrickson 480-256-6444 | |
United States, California | |
University of Southern California - Norris Comprehensive Cancer Center | Recruiting |
Los Angeles, California, United States, 90033 | |
Contact: Dr Yaghmour 323-865-3170 | |
University of California San Diego, Moores Cancer Center | Recruiting |
San Diego, California, United States, 92093 | |
Contact: Benjamin Heyman 858-822-6100 bheyman@health.ucsd.edu | |
United States, District of Columbia | |
Medstar Georgetown University Hospital | Recruiting |
Washington, District of Columbia, United States, 20007 | |
Contact: Dr. Renteria 202-444-0939 Anne.Renteria@medstar.net | |
United States, Kentucky | |
University of Kentucky - Markey Cancer Center | Recruiting |
Lexington, Kentucky, United States, 40536 | |
Contact: Dr. Chaitanya Iragavarapu 859-257-4488 c.iragavarapu@uky.edu | |
United States, Michigan | |
Henry Ford Hospital | Recruiting |
Detroit, Michigan, United States, 48202 | |
Contact: Dr Mattour 313-916-1266 | |
United States, North Carolina | |
Levine Cancer Institute | Recruiting |
Charlotte, North Carolina, United States, 28204 | |
Contact: Dr Moyo 980-442-2301 | |
United States, Ohio | |
University of Cincinnati Medical Center | Recruiting |
Cincinnati, Ohio, United States, 45229 | |
Contact: Dr Latif 513-584-7824 | |
Oncology Hematology Care, Inc-Kenwood | Recruiting |
Cincinnati, Ohio, United States, 45236 | |
Contact: Dr. James Essell 513-751-2273 james.essell@usoncology.com | |
United States, Tennessee | |
Vanderbilt University Medical Center | Recruiting |
Nashville, Tennessee, United States, 37232 | |
Contact: Dr. Olalekan Oluwole 615-875-0060 olalekan.oluwole@vumc.org | |
United States, Texas | |
Houston Methodist Research Institute | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Dr. Pingali 713-441-9948 spingali@houstonmethodist.org | |
United States, Virginia | |
Virginia Oncology Associates | Recruiting |
Norfolk, Virginia, United States, 23502 | |
Contact: Dr. Scott Cross 757-466-8683 scott.cross@usoncology.com | |
United States, Washington | |
Swedish Cancer Institute | Recruiting |
Seattle, Washington, United States, 98104 | |
Contact: Dr Patel 206-386-2301 |
Responsible Party: | Century Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT05336409 |
Other Study ID Numbers: |
CNTY-101-111-01 (ELiPSE-1) |
First Posted: | April 20, 2022 Key Record Dates |
Last Update Posted: | April 23, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Lymphoma, Non-Hodgkin Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular Lymphoma, B-Cell, Marginal Zone Cellular therapy Cell therapy |
CNTY-101 Century Therapeutics Induced pluripotent stem cells CAR-NK NK cell |
Lymphoma Neoplasms Lymphoma, Non-Hodgkin Neoplasms by Histologic Type |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |